Research programme: atherosclerosis therapeutics - Entos Pharmaceuticals
Latest Information Update: 29 Sep 2020
At a glance
- Originator Entos Pharmaceuticals
- Developer Entos Pharmaceuticals; Repair Biotechnologies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atherosclerosis
Most Recent Events
- 07 Sep 2020 Early research in Atherosclerosis in Canada (unspecified route) before September 2020 (Entos Pharmaceuticals pipeline)
- 07 Sep 2020 Early research in Atherosclerosis in USA (unspecified route) before September 2020 (Entos Pharmaceuticals pipeline)